GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medifast Inc (MED) [hlAlert]

Rating:
Hold MED
up 20.77 %

Medifast Inc (MED) downgraded to Hold by Standpoint Research

Posted on: Monday,  Jul 9, 2012  10:25 AM ET by Standpoint Research

Standpoint Research rated Hold Medifast Inc (NYSE: MED) on 07/09/2012. Previously Standpoint Research rated Buy Medifast Inc (NYSE: MED) on 01/30/2012.,
when the stock price was $16.75. Since then, Medifast Inc has gained 20.78% as of 07/09/2012's recent price of $20.23.
If you would have followed the previous Standpoint Research's recommendation on MED, you would have gained 20.77% of your investment in 161 days.

Medifast, Inc. (Medifast) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company?s product lines include weight and disease management, meal replacement, and vitamins primarily manufactured in its modern, the United States Food and Drug Administration (FDA) approved facility in Owings Mills, Maryland. The Company?s operations are primarily conducted through five of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSF), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. The Company offers a variety of weight and disease management products under the Medifast brand and for select private label customers. It's distribution channels include Medifast Direct, Take Shape for Life, Medifast Weight Control Centers and Medifast Physicians.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/9/2012 10:25 AM Hold
None
20.23
as of 12/31/2012
1 Week   
1 Month   
3 Months   
1 YTD up  20.77 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/30/2012 10:25 AM Buy
None
16.75 24.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy